X4 Pharmaceuticals, Inc revenue
X4 Pharmaceuticals, Inc's revenue was $35.1m in fiscal 2025, up 1250.5% on the year before. Since fiscal 2020 ($3.0m) it has grown at a compound 63.6% a year. Over the last twelve months it was $15.4m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| License and Other Revenue | $28.6M | 81.4% | — |
| Products | $6.5M | 18.6% | ▲ 155.1% |
From X4 Pharmaceuticals, Inc's 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| X4 Pharmaceuticals, Inc | $15.4m | -52.6% | — |
| Keros Therapeutics, Inc. | $14.9m | -93.6% | — |
| Alector, Inc. | $13.9m | -82.9% | -48.6% |
| Proqr Therapeutics N.V. | $18.0m | -12.1% | — |
| Lineage Cell Therapeutics, Inc. | $13.1m | 19.9% | 7.5% |
| Cytomx Therapeutics, Inc. | $18.3m | -87.0% | -38.7% |
Compare with peers
- Keros Therapeutics, Inc. revenue
- Alector, Inc. revenue
- Proqr Therapeutics N.V. revenue
- Lineage Cell Therapeutics, Inc. revenue
- Cytomx Therapeutics, Inc. revenue
Head to head: KROS vs XFORALEC vs XFORPRQR vs XFOR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies